MedTrace Logo

A Phase II Study of SYHA1813 for Recurrent or Progressive High-Grade Meningioma

NCT06739213 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2024-12-18

No results posted yet for this study

Summary

This is a randomized, controlled, open-label, multicenter, Phase II clinical study designed to evaluate the efficacy and safety of SYHA1813 compared to investigators' choice in participants with recurrent or progressive high-grade meningioma.

Conditions

  • Recurrent or Progressive High Grade Meningioma

Interventions

DRUG

SYHA1813

The starting dose of SYHA1813 is 20mg QD

DRUG

Investigator's Choice Treatment

Investigator's Choice Treatment

Sponsors & Collaborators

  • Shanghai Runshi Pharmaceutical Technology Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-31
Primary Completion
2027-01-31
Completion
2028-01-13

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06739213 on ClinicalTrials.gov